MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...
Healthline5d
6 Step Guide for Self-Care with Psoriatic Arthritis
These 6 self-care tips may help you better manage your psoriatic arthritis symptoms. Psoriatic arthritis affects the body in two ways. In addition to producing joint pain and stiffness ...
Too Old to Operate1d
Dissatisfaction With Multiple Facets of Care Reported in Psoriasis & Psoriatic Arthritis
Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...
JD Supra3d
Celltrion Launches STEQEYMA (ustekinumab) in Germany and the Netherlands
As we previously reported, this August the European Commission granted approval for Celltrion’s STELARA biosimilar, STEQEYMA. Earlier this ...
Promising Outlook for MoonLake’s Sonelokimab in Psoriatic Arthritis Treatment
MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.
Nasdaq6d
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
in patients with active psoriatic arthritis (PsA). PsA is a chronic, debilitating and progressive inflammatory condition that not only affects the peripheral joints and skin but also other domains ...
Taiwan News5d
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve patients and including evaluation of radiographic progression (IZAR-1), and the other focusing on TNF-IR patients ...
Mena FN6d
Moonlake Immunotherapeutics Starts Phase 3 IZAR Program Of The Nanobody® Sonelokimab In Patients With Active Psoriatic Arthritis
Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve patients and including evaluation of radiographic progression (IZAR-1), and the other focusing on TNF-IR ...